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ABSTRACT 
 
 A hallmark of Alzheimer’s Disease (AD) is the aggregation of hyperphosphorylated tau 
protein into neurofibrillary tangles. Tau localizes to both the cytoplasm and the nucleus of 
neuronal cells; however, its nuclear role has not been fully defined. Tau has recently been shown 
to bind to purine-pyrimidine (R/Y) repeats in DNA and stabilize them into Z-DNA. Evidence 
from our lab suggests that the binding of tau to R/Y repeats causes transcriptional changes of the 
NOS1 gene. Six major isoforms of tau exist in neurons. These isoforms fall into two groups, 
denoted as 3R tau and 4R tau, and are found at an equal ratio in healthy whole-cell extracts. 
During AD progression, an imbalance of 3R and 4R tau occurs, along with changes in NOS1 
expression and a buildup of Z-DNA in severe AD patients. Based on studies of mouse tau and 
our lab’s previous work, we hypothesized that the 3R and 4R tau would be found in equal ratios 
in the nucleus of normal human cells, and that tau would bind to the NOS1 R/Y repeat. To test 
these hypotheses, western blotting of nuclear proteins from human neuroblastoma cells (SK-N-
MC) and antibodies for specific tau isoforms were used to examine which isoforms were found 
in SK-N-MC cells. Additionally, electrophoretic mobility shift assays (EMSAs) were developed 
to better understand tau’s ability to bind R/Y repeats using the R/Y repeat from the NOS1 gene. 
The western blots showed that the 3R isoform of tau predominates in SK-N-MC cells, that 
similar tau isoforms are present in the nuclear, cytoplasmic, and chromatin- bound fractions, and 
that a majority of nuclear tau exists bound to DNA. Our EMSAs showed that some nuclear 
protein binds the NOS1 R/Y repeat, this protein has not been identified. Future experiments will 
use western blotting to characterize nuclear tau in other cell lines, continue improving our 
EMSAs, and identify the NOS1 R/Y repeat binding protein. 
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INTRODUCTION 
 
Alzheimer’s Disease (AD), an incurable neurodegenerative disorder, is the sixth leading 
cause of death in the United States. AD can significantly impair one’s ability to think, remember, 
communicate, and carry out daily activities. It is projected that by 2050, the number of 
Americans living with AD could rise to 14 million (Alzheimer’s Association, 2018). Due to the 
severity of this disease and the continuous increase in its incidence, it is critical that we 
investigate the molecular mechanisms of the neurodegeneration in patients with AD. 
A major hallmark of AD is the aggregation of hyperphosphorylated tau protein into 
neurofibrillary tangles (NFTs) (Lee et al., 2001). Tau, or tubulin-associated unit, was first 
discovered as a protein factor that promotes the stability of microtubules in the cytoplasm, 
though it has been discussed to have synaptic and nuclear localizations as well (Lippens et al., 
2016; Sultan et al., 2011; Vasudevaraju et al., 2012; Liu and Gotz, 2013). Tau binding to 
microtubules is regulated by phosphorylation. Phosphorylated tau dissociates from microtubules 
and allows the microtubules to depolymerize. Under pathological conditions, tau 
phosphorylation is increased, resulting in destabilizing microtubules and potentially leading to 
neuronal collapse (Guo et al., 2017). Moreover, sometimes tau can be hyperphosphorylated in 
disease. Hyperphosphorylated tau can be truncated and, therefore, stay in the cytoplasm, often 
aggregating into NFTs. It is unknown if free truncated tau or the NFTs themselves are more toxic 
to the cell. Some studies suggest that NFTs are toxic, while others suggest that NFTs are a 
protective cellular mechanism against free truncated tau (Mania et al., 2015). Regardless of the 
uncertainty surrounding NFTs’ effects, the presence of NFTs are central to the diagnosis of AD 
and are highly correlated to memory loss occurring in AD (Guillozet et al., 2003). 
 7 
Human tau is encoded by the MAPT gene located on chromosome 17. In neurons, the tau 
protein has six major isoforms generated by alternative splicing. A seventh isoform is also found 
in non-neuronal cells (Goedert et al., 1989; Janke et al., 1996). The six major isoforms vary due 
to the presence or absence of exons 2, 3, and 10. Exons 2 and 3 contain N terminal domains. 
Isoforms lacking exon 2 and 3 contain 0 N domains, while isoforms containing exon 2 contain 1 
N domain, and finally isoforms containing both exon 2 and 3 have 2 N-terminal domains. 
Isoforms containing exon 10 have four microtubule binding domains (4R) and isoforms missing 
this exon have three microtubule binding domains (3R) (Figure 1). 
Figure 1. A representation of the six major isoforms of tau and the seventh isoform, big 
tau, translated from the UCSC Genome Browser. The 3R and 4R tau isoforms also have 0N, 
1N, and 2N domains, and are denoted 0N4R (2-, 3-, 10+), 1N4R (2+, 3-, 10+), 2N4R (2+, 3+, 
10+), 0N3R (2-, 3-,10-), 1N3R (2+, 3-, 10-), and 2N3R (2+, 3+, 10-). The big tau isoform is the 
only isoform that includes exon 4A. 
 
The six major isoforms are denoted 0N4R (2-, 3-, 10+), 1N4R (2+, 3-, 10+), 2N4R (2+, 
3+, 10+), 0N3R (2-, 3-,10-), 1N3R (2+, 3-, 10-), and 2N3R (2+, 3+, 10-) because of their exon 
content (Goedert et al., 1989). Both N-domain and R-domains have been shown to have an 
affinity to DNA (Qi et al., 2015). The seventh, less common form of tau, is known commonly as 
“big tau” and is the full transcript, including the 4A exon (Janke et al., 1996). 
In healthy human adult brain tissue, the 3R and 4R isoforms exist at an equal ratio. 
However, it has been observed that the ratio between the 3R and 4R is distorted in the AD brain, 
suggesting that these isoforms have different functions (Hong et al., 1998). This has been 
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identified as an important area of research, and a model that has been used is the brains of 
rodents. Unfortunately, adult rodent brains only contain the 4R isoforms of tau, making it 
difficult to compare studies done in rodents and those done in humans. In the nucleus of mice 
neurons, the 1N4R isoform is the most predominant isoform, though 0N4R and 2N4R were also 
found (Liu and Gotz, 2013). Therefore, furthering our understanding of the isoforms of tau that 
are naturally present in the nucleus will help us increase our knowledge of nuclear tau and give 
insight how an imbalance of subunits in AD may affect nuclear functions. 
Several different potential roles for tau have been found in the nucleus. Tau’s DNA 
binding is known to participate in the repair process of cells. One group has found that tau binds 
to DNA, potentially protecting DNA from damage caused by double strand breaks (Liu and 
Gotz, 2013). Although the nature of this protective mechanism is unknown, Liu and Gotz 
showed that higher levels of tau are associated with less double-stranded DNA breaks, and 
conversely less tau is associated with more double-stranded DNA breaks. Other studies have 
suggested protective roles for tau as well. Sultan et al. demonstrated that tau binding DNA 
protected it against heat shock induced double strand breaks, suggesting that tau is critical to 
early stress responses in neuronal cells (Sultan et al., 2011). Another study proposed that tau 
localized in the nucleus and the plasma membrane of neurons has a role in DNA repair and inter-
neuron signaling through an unknown process that could be regulated through nuclear processes 
(Hanger et al., 2014). The 1N tau isoform shows the most affinity for DNA, likely being the 
greatest protector of DNA (Liu and Gotz, 2013). Tau has also been studied as a potential 
therapeutic target for the treatment and prevention of other neurological pathologies like epilepsy 
(Sotiropoulos et al., 2017). Thus, it is possible that alteration in tau during AD may be 
responsible for damaging changes in DNA structure that contribute to AD. 
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In addition to a potential role in protection of DNA, another nuclear function of tau has 
been shown to involve DNA binding. It is now known that tau in its unphosphorylated form 
localizes to the nucleus, although a specific DNA binding site for tau has not yet been identified. 
Several studies suggest tau binds preferentially to purine-pyrimidine (R/Y) repeats in the DNA 
(Sultan et al., 2011; Vasudevaraju et al., 2012; & Liu and Gotz, 2013). R/Y repeats can often be 
found in promoter regions and can potentially cause DNA in the repeat region to switch into 
alternative forms, such as Z-DNA, changing gene transcription (Cox et al., 2012). It has been 
shown that the tau protein is capable of binding to and stabilizing a R/Y oligonucleotide in both 
the B-DNA and Z-DNA conformation. Moreover, AD neurons in late-stage patients contain 
excessive Z-DNA, as identified in circular dichroism studies of post-mortem brains 
(Vasudevaraju et al., 2012). This suggests that tau binding to DNA may change as the disease 
progresses 
Tau has also been suggested by our lab to regulate the transcription of the nitric oxide 
synthase gene (NOS1). The NOS1 enzyme produces the secondary messenger nitric oxide (NO), 
which is crucial for the regulation of a variety of body functions including controlling blood 
pressure, long-term memory, and synapse formation (Toda and Okamura, 2003; Prast, 2001). 
NOS1 transcription must be tightly regulated, as excess NO can have neurotoxic effects, while 
low levels can have neuroprotective effects (Sultana et al., 2006). NOS1 is transcribed from 12 
different promoters (1A-1L), one of which, 1F, has a TG repeat polymorphism which can range 
in size from 40-65 repeated TG nucleotides (Hall et al., 1994). A smaller polymorphic repeat in 
the 1F promoter leads to an increased risk of developing AD and Parkinson’s disease, another 
neurodegenerative disease (Galimberti et al., 2008, Rife et al., 2009). Work previously done in 
our lab using promoter deletion studies show that a cell with higher expression of tau also has a 
 10 
change in NOS1 transcription, though this only occurs when the R/Y repeat is present in the 
promoter region of NOS1 (Weaver and Deal, 2016). This has been an area of interest to our lab, 
as not only does NOS1 contain this type of R/Y repeat, but many of the genes in Alzheimer’s do 
(Kimpara et al., 1997; Lambert et al., 1998; Ueki et al., 2007). Thus, it is of great importance to 
better understand how this repeat functions and gain evidence about the mechanism by which the 
change in NOS1 expression occurs. Whether NOS1’s R/Y repeat is able to interact directly with 
the tau protein or another protein that is affected by changes in tau is unknown. Studying tau’s 
potential interaction with the NOS1 could give greater insights as to a new gene regulation 
mechanism for tau in the nucleus during Alzheimer’s disease, beyond tau’s cytosolic role in 
stabilizing microtubules. 
 Other than the data from our lab, no other studies have been done to show that tau can 
regulate transcription, but several other groups have suggested this possibility. One study 
examined possible ways through which tau may act as a transcription factor. Sultan et al. 
observed that tau binds into the minor groove of DNA, which causes a kink in the strand that 
helps promoters to bend and interact with transcription factors (Sultan et al., 2011). To more 
completely understand the role of tau in the nucleus and its binding mechanism to R/Y repeats, a 
DNA binding study is necessary. 
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Specific Aims: 
Aim 1: To determine the isoforms of tau normally found in the nucleus of human SK-N-
MC cells. 
While six major isoforms of tau (4R isoforms with 0N, 1N or 2N, and 3R isoforms with 
0N, 1N, or 2N domains) have been identified in whole-cell extracts of human neurons, the tau 
isoforms found specifically in human nuclei have not yet been identified. Although mouse 
studies have found a predominance of the 1N4R isoform, mice do not contain any of the 3R 
domains. Based on studies of mouse neurons and the known ratios of 3R to 4R in humans, we 
hypothesize that the 1N3R and 1N4R tau isoform will be predominate in the human nucleus (Liu 
and Gotz, 2013). 
              To test this hypothesis, SK-N-MC cells, human neuroblastoma cells, were used because 
they have high levels of nuclear tau and have been used in previous studies to understand tau 
function. Proteins from these cells were fractionated into cytoplasmic and nuclear portions and 
run on SDS-page gels. Western blots using antibodies specific to different tau isoforms were 
used to identify which isoforms are found in the nucleus. 
Aim 2: To determine the possible transcription factor(s) that bind to the NOS1 
polymorphism.  
It is well known that tau has DNA binding affinity, especially towards sequences with 
R/Y repeats. From previous studies in our lab, we know that either tau or another agent that is 
regulated by changes in tau expression can change the expression of the NOS1 gene with a R/Y 
repeat polymorphism in its promoter region (Weaver and Deal, 2016). However, the mechanism 
by which either tau or another agent is changing the expression of this gene is unknown. The 
R/Y repeat of the NOS1 gene is rich in TG nucleotide repeats, which can form both B-DNA and 
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Z-DNA (Bothe et al., 2011). Tau has been shown to have an affinity towards both B-DNA and 
Z-DNA, though only high levels of Z-DNA are found in Alzheimer’s brains (Vasudevaraju et 
al., 2012). In studies which analyzed tau’s affinity towards R/Y repeats, it was found that tau has 
the greatest affinity towards TA nucleotide repeats, followed by TG, AC, and CG, in that order 
(Sultan et al., 2011; Vasudevaraju et al., 2012). Based on studies of tau’s DNA binding affinities 
and previous work in our lab, we hypothesize that it is tau binding the R/Y repeat of NOS1, 
acting as a transcription factor to change the gene’s expression. 
To learn more of how tau or another agent could be changing NOS1 expression, 
electrophoretic mobility shift assays (EMSA) will be used to determine the nature of the binding 
particle through modifying methods outlined by Dent and Latchman, and Berman et al. (1993; 
1987). The goal of each EMSA is to determine a difference in mobility between control samples 
of only DNA, referred to as just DNA controls (JDC), and samples containing both the DNA and 
potential binding proteins, referred to as mobility shift attempts (MSA). Nuclear fractions from 
SK-N-MC cells will be run on an agarose gel with a short piece of DNA containing the NOS1 
polymorphism (NOS1 probe) to act as MSA samples and compared to JDC samples containing 
only the NOS1 probe in order to determine a band shift, providing evidence that something is 
binding to the NOS1 polymorphism. Furthermore, a secondary band shift utilizing a total tau 
antibody, or a purified sample of tau, will be used to show whether tau is or is not the binding 
particle for the NOS1 probe. 
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METHODS 
 
SK-N-MC Cell Maintenance: 
SK-N-MC (human neuroblastoma) cells were grown in 8mL of Eagles Modified Minimal 
Medium with 2mM L-glutamine, 10% fetal bovine serum, and 100 units/ml 
penicillin/streptomycin on a 100 mm tissue-culture treated cell culture dish and harvested with 
0.25% trypsin-EDTA. For maintenance, media was vacuumed off the cell plates at 70-90% 
confluency and replaced with 2mL of 0.25% trypsin-EDTA. After roughly 60 seconds of 
trypsinization, the trypsin was removed and 4mL of media was added to rinse the cells from the 
plate. These cells were split into two or more plates and media was added to make a total volume 
of 8mL.  
Cellular Fractionation and Total Protein Assay: 
Two separate kits were used to obtain cellular fractions. The Thermo Scientific™ NE-
PER™ Nuclear and Cytoplasmic Extraction Kit for a collection of two fractions containing the 
cytoplasm and the nucleus; and Thermo Scientific Subcellular Proteion Fractionation Kit for 
Cultured Cells was used to collect five subcellular fractions containing the cytoplasm, 
membrane, nucleus, chromatin, and cytoskeleton. In the procedure for both kits, extra care was 
taken to never disturb the pellet while collecting supernatants, and to leave the pellet completely 
absent of supernatant after collection. Immediately following each step which required a 
centrifugation and subsequent collection of the supernatant, a second, short centrifugation was 
added in order to ensure that all liquid was removed from the pellet. During the second removal 
of supernatant from the pellet, there were cases in which the pellet had to be disturbed in order to 
leave the pellet completely dry. When the pellet must be disturbed, the supernatant collected was 
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disposed of as to not contaminate any fractions. After the completion of all steps in either 
fractionation protocol, each fraction was immediately analyzed with a total protein assay. 
Thermo Scientific™ NE-PER™ Nuclear and Cytoplasmic Extraction Kit (2FK): 
All solutions were ice-cold, all samples were kept on ice, all incubations were at 4
0
 C, all 
vortexing was done on the highest setting, and Thermo Scientific Halt™ Protease Inhibitor 
Cocktail was added to all solutions unless otherwise noted. Cytoplasmic extraction reagent I 
(CERI), cytoplasmic extraction reagent II (CERII), and nuclear extraction reagent (NER), were 
all used. Each buffer added was adjusted to the packed cell volume in the sample. 
Roughly 1-10x10
6
 cells suspended in PBS (no protease inhibitor) were centrifuged at 500 
x g for 2-3 minutes. The supernatant was discarded and CERI was added. The sample was then 
vortexed for 15 seconds to resuspend pellet and incubated for 10 minutes. CERII (no protease 
inhibitor) was added to the sample, vortexed for 5 seconds, incubated for 1 minute, vortexed for 
another 5 seconds. The sample was centrifuged at 16,000 x g for 5 minutes and the supernatant 
(cytoplasmic extract) was collected. NER was added to the pellet and resuspended through a 
process of 4 consecutive 15 second vortexes and 10 minute incubations for a total 40 minutes. 
The sample was then centrifuged at 16,000 x g for 10 minutes and the supernatant was collected. 
Thermo Scientific™ Subcellular Protein Fractionation Kit for Cultured Cells (5FK): 
All solutions were ice-cold, all samples were kept on ice, all incubations were at 4
0
 C and 
done with gentle mixing, all vortexing was done on the highest setting, and Thermo Scientific 
Halt™ Protease Inhibitor Cocktail was added to all solutions unless otherwise noted. 
Cytoplasmic extraction buffer (CEB), membrane extraction buffer (MEB), nuclear extraction 
buffer (NEB), and pellet extraction buffer (PEB) were all used. Each buffer added was adjusted 
to the packed cell volume in the sample. 
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Roughly 1-10x10
6
 cells suspended in PBS (no protease inhibitor) were centrifuged at 500 
x g for 2-3 minutes. The supernatant was discarded, CEB was added, and incubated for 10 
minutes. The sample was centrifuged at 500 x g for 5 minutes and the supernatant (cytoplasmic 
extract) was collected. MEB was added to the pellet, vortexed for 5 seconds, and incubated for 
10 minutes. The sample was centrifuged at 3000 x g for 5 minutes and the supernatant 
(membrane extract) was collected. NEB was added to the pellet, vortexed for 15 seconds, and 
incubated for 30 minutes. The sample was centrifuged at 5000 x g for 5 minutes and the 
supernatant (soluble nuclear extract) was collected. Chromatin-bound extraction buffer was 
prepared with CaCl2, micrococcal nuclease, and room temperature NEB and then added to the 
pellet, vortexed for 15 seconds, incubated in a 37
0
 C water bath for 5 minutes, followed by 
another 15 second vortexing. The sample was centrifuged at the highest centrifuge setting for 5 
minutes and the supernatant (chromatin-bound extract) was collected. Room temperature PEB 
was added to the pellet, vortexed for 15 seconds, and incubated for 10 minutes. The sample was 
centrifuged at the highest centrifuge setting for 5 minutes and the supernatant (cytoskeletal 
extract) was collected. 
Total Protein Assay:  
         The collected fractions were analyzed using a total protein assay (Bio-Rad). 
Absorbance was measured at 340 nm for five known standards containing 0.25 µg/µL, 0.5 
µg/µL, 0.75 µg/µL, 1.0 µg/µL, and 1.25 µg/µL of bovine serum albumin in 1.5 mL of protein 
expression buffer to create a standard curve (R
2 
> 0.9). This curve was then used to calculate the 
concentration of each fraction taken. After the completion of the total protein assay, each fraction 
was aliquoted and flash-frozen in liquid nitrogen and stored in a -80
0
 C freezer for future use. 
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Western Blot: 
The protein extracts from the fractionation experiment were thawed and mixed with a 
pipette. 10 µg of each extract were diluted and placed into PCR tubes with 15uL of 2X Sample 
Loading Buffer, keeping the sample to dye ratio 1:1. These samples were denatured by heating 
them in a boiling water bath for five minutes. Each extract was run on a 12% Mini-Protean TGX 
Stain-Free Precast gels (Bio-Rad) at 200V until the blue dye reached the bottom of the gel. The 
Bio-Rad Chem-Doc was used to photograph the gels. 
The gels were placed into individual trays and soaked in chilled 1X Western Transfer 
Buffer, diluted from Bio-Rad 10X Western Transfer Buffer (200mL methanol, 100mL 10X 
Tris/Glycine buffer, 4g SDS, and 700mL dH2O), for 10 minutes. An Immunoblot PVDF 
membrane (Bio-Rad) was prepared. The membrane was cut to be the same size as the gels and 
soaked in methanol until it becomes slightly translucent. The membrane was then soaked in H2O 
for 3-4 minutes and put on a rotating shaker. The membrane was then soaked in 1X Western 
Transfer Buffer (Bio-Rad) for 5 minutes. The materials were placed into the transfer cassette as 
following: sponge, Whatman filter paper, gel, PDVF membrane, Whatman filter paper, sponge. 
The gel and membrane were placed very carefully so that there were no bubbles and the 
membrane lined up with the gel. The transfer cassette was placed into an electrophoresis tank 
and the remaining 1X Western Transfer Buffer was added. The gel was run on a magnetic plate 
in the cold room at a constant current of 250mA with constant stirring. The membranes were 
blocked in a sealed tray with a standard blocking solution containing 0.2% nonfat dry milk in 1X 
Tris-Buffered Saline and Tween 20 (TTBS) buffer solution. 
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Antibody Detection: 
The blocking buffer from the previous procedure was removed from the membrane and 
the blot was rinsed with TTBS (Bio-Rad) on a rotating shaker two times for 5 minutes each. 
While the membrane was washed, the primary antibody was prepared on ice using the dilutions 
listed in Table 1. We used five primary antibodies — a histone 2A (H2A) antibody to detect the 
nuclear and chromatin proteins, a glyceraldehyde phosphate dehydrogenase (GAPDH) antibody 
to detect cytoplasmic proteins, a total tau antibody (TAU-13), a 3R tau antibody (3RT), and a 4R 
tau antibody (4RT). These were utilized to ensure the nuclear fraction was pure and that similar 
amounts of proteins were loaded into each lane of the gel. 
Table 1. Antibodies and dilutions used for detection. 
Primary Antibody Dilution Secondary Antibody Dilution 
H2A 
(Millipore Cat #07-146) 
Lot #2880714 
1:5000 — 1 hour RT 
3uL in 15mL TTBS 
AP Conjugated Affinity 
(Millipore Cat. #AP307A) 
Lot #2912084 
 
HRP Conjugated Affinity  
(Millipore Cat. #AP187P) 
Lot #2709676 
1:3000 — Overnight 4
0
C 
5uL in 15mL TTBS 
GAPDH 
(Millipore Cat. #AB2302) 
Lot #2967896 
1:2000 — 1 hour RT 
7.5uL in 15mL TTBS 
Chicken — Anti-HRP 
(Millipore Cat. #AB2302) 
Lot #2424824 
1:12,000 — 1 hour RT 
1.25uL in 15mL TTBS 
TAU-13 
(Santa Cruz: sc-21796) 
1:2000 — 1 hour RT 
7.5uL in 15mL TTBS 
Mouse — Anti-HRP 
(Millipore Cat. #AP181P) 
 
1:2,000 — 1 hour RT 
7.5uL in 15mL TTBS 
3R Tau 
(Millipore Cat. #05-803) 
Lot #2373392 
 
1:3000 — 1 hour RT 
7.5uL in 15mL TTBS 
Mouse — Anti-HRP 
(Millipore Cat. #AP181P) 
 
1:2,000 — 1 hour RT 
7.5uL in 15mL TTBS 
4R Tau 
(Millipore Cat. #05-804) 
Lot #2880714 
 
1:3000 — 1 hour RT 
7.5uL in 15mL TTBS 
Mouse — Anti-HRP 
(Millipore Cat. #AP181P) 
 
1:2,000 — 1 hour RT 
7.5uL in 15mL TTBS 
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The final TTBS wash was dumped and approximately 15mL of the primary antibody 
solution was added to the tray. The membrane and antibody were incubated at room temperature 
for an hour while on a shaker. The primary antibody was discarded and the membrane was 
washed multiple times with TTBS while shaking. The secondary antibody was then prepared on 
ice using the dilutions listed in Table 1. This solution was placed onto the membrane and 
incubated for one hour at room temperature while shaking. The membrane was washed three 
times with TTBS for five minutes each. These antibodies were stained with horse-radish 
peroxidase (HRP) or alkaline phosphatase (AP) and corresponding HRP (Bio-Rad #170-5041) 
and AP (Bio-Rad Cat. #170-5014) detection kits were used. When using the HRP detection kit, 
Immun-Star HRP Luminol/Enhancer was mixed with Immun-Star HRP Peroxide Buffer in a 1:1 
ratio for a total volume of 2-5mL based on the membrane size. This solution was then added to 
the membrane and incubated for five minutes. When using the AP detection kit, 2-5mL of 
Immun-Star Substrate was added to the membrane and incubated for five minutes. In both 
procedures, excess enhancer solution was removed before the membrane was exposed to light. 
Chemi-luminescence was detected using a Chemi-doc system (Bio-Rad) and band intensities 
were determined using the Chemi-doc software package. 
Relative Quantification of Tau Isoforms on Western Blot by Gel Densitometry  
 After western blotting was completed, gel densitometry was completed using 
ImageLab software (Bio-Rad) to quantify the amount of each band detected in the cytoplasm, 
nucleus, and chromatin relative to the total amount of protein found in all of the fractions. To do 
this a gel densitometry report was generated by the ImageLab software with volume 
measurements for the bands in each lane. These volume measurements were all added together to 
get the total volume density for the membrane. The volume measurement of each individual 
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band was then compared to the total volume density of the membrane and converted into a 
percentage of protein detected. See Appendix I for full protocol. 
Band Shift Detection: 
A basic outline for EMSAs was found from Dent and Latchman and Berman et al. (1993; 
1987). The procedure of detecting band shifts had many changes made to it in order to determine 
the optimal procedure. The process of forming double stranded DNA, staining/destaining the gel, 
and detection of bands were standard. All other factors such as DNA amount, protein amount, 
protein sample content, binding reaction buffer, binding reaction incubation time, loading dye 
presence, agarose gel concentration, electrophoresis voltage, and electrophoresis time were all 
varied in different experiments. 
To make double stranded DNA, both of the 58 bp forward and reverse strands of the 
NOS1 probe are denatured in a PCR cycler at 95
o
C for three minutes, and annealed at 65
o
C for 
one hour. This forms our just DNA control samples (JDC samples). 
Figure 2. The NOS1 probe. The top strand shows the forward primer, and the bottom strand 
shows the reverse primer. The two sequences aligned together as shown form the NOS1 probe. 
 
The double stranded DNA (5-10 µg) was then mixed with a sample of protein (5-25 µg of 
nuclear fraction proteins from 5FK or 2FK, or a somewhat purified tau sample) and binding 
reaction buffer (PBS (1X PBS, pH 7.4), Tris (20 mM Tris-HCl, pH 7.2-7.6), or Hepes (10 mM 
Hepes, 12.5% glycerol, 50 mM KCl, 12mM MgCl2 pH 7.5)) to a total volume of 18 uL for PBS 
or Tris buffers, or 24 uL for Hepes buffers (MSA samples). The MSA samples were incubated at 
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4
0
 C (achieved by either incubating on ice or in the 4
0
 C cold room) for 30-90 minutes. When 
Tris or PBS buffer was used, the samples needed to be mixed with 4X loading dye to a final total 
volume of 24 uL; Hepes buffer did not require the addition of loading dye. All samples were 
loaded on to a large 2-3% (w/v) agarose gel and run at 30-100 V in 1X TAE for 5-24 hours. 
When agarose concentrations above 2% were used, the agarose was left in 1X TAE buffer for 15 
minutes prior to a very slow heating process, avoiding boiling of the solution. 
 To perform a secondary shift, either the normal protein sample was changed to a more 
purified sample of tau, or an antibody was added to the MSA sample incubation mixture. To 
obtain a more purified sample of tau, Barghorn et al. outlines a purification from whole-cell 
lysates involving boiling the sampling for 20 minutes with 0.5M NaCl and centrifuging at 
127,000g for 40 minutes at 4
0
 C, which removed nearly all proteins of lower molecular weight 
than tau (2005). When adding an antibody to the reaction mixture, the NOS1 probe and protein 
sample must incubate without the antibody for 30 minutes, then the 1 µg of antibody may be 
added. Each antibody useful in these secondary shift EMSAs existed at different concentrations, 
and thus different volumes were used accordingly: 5 µL of total tau antibody = roughly 1 µg, 10 
µL of 3R tau antibody = 1 µg, 1 µL of GAPDH antibody = 1 µg. Appropriate controls must also 
be added to an EMSA which utilized an antibody. A normal JDC and MSA sample were run next 
to the MSA sample containing antibody, as well as a JDC sample with the same amount of 
antibody and no protein, and another MSA sample with the same amount of an unrelated 
antibody, such as the one for GAPDH. 
The final gel was stained with a 0.5 µg/ml ethidium bromide solution for 15 minutes and 
destained in dH2O for 5 minutes. The Bio-Rad Chem Doc was used to photograph the gel to 
detect the bands. 
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RESULTS 
 
Western Blot and Antibody Detection:      
 Western blotting was completed with antibodies specific to different tau isoforms to 
identify which isoforms are found in different subcellular fractions. We obtained a total of two 
fractions using the 2FK fractionation kit: cytoplasmic and nuclear; and five fractions using the 
5FK fractionation kit: cytoplasmic, membrane, soluble nuclear, chromatin-bound, and 
cytoskeletal. Each fraction was ran on a gel and it was confirmed that there was some functional 
protein present in each fraction (Figure 3).  
Figure 3. Gel analysis displaying the presence of protein in all fraction samples. 
Approximately 10μg of protein from the cytoplasmic (CY), chromatin (CH), and nuclear (N) 
fractions were run on a 12% Mini-Protean TGX Stain-Free Precast gels (Bio-Rad) at 200V. 
Presence of similar amounts of protein was observed in each fraction, allowing us to proceed to a 
western blot analysis. 
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We determined that the 2FK fractionation protocol yielded the expected fractions, using 
GAPDH as a marker for the cytoplasmic fraction and histone H2A as a marker for the nuclear 
fraction. A strong positive band of 38 kDa is present in the cytoplasmic fraction for GAPDH, and 
a very faint potential band of 17 kDa was detected in the nuclear fraction for H2A (Figure 4A). 
Figure 4. Antibody analyses of two subcellular fractions from SK-N-MC cells. 
Approximately 10 µg of DNA in both fractions was loaded onto a gel and then transferred onto a 
PVDF membrane. (A) Relative purity of the cytoplasmic (CY) and nuclear (N) fractions were 
confirmed using GAPDH and H2A antibodies. (B) Presence or absence of the tau isoforms 
located in the two fractions after exposure to Total Tau (TAU-13) antibody. (C) Presence or 
absence of the 3R and 4R tau isoforms distributed in both fractions. 
 
Next, we determined the distribution of the Total tau, the 3R tau, and the 4R tau isoforms 
in these fractions (Figure 4B, 4C). Analysis using an antibody against all tau isoforms (TAU-13) 
revealed that numerous tau isoforms were present in the cytoplasm and nucleus, showing bands 
between 35 and 50 kDa that appear to be equal strength (Figure 4B). When a 3R tau antibody 
was used for detection, similar detection patterns were observed in the cytoplasmic and nuclear 
fractions, but the amount of tau appeared to be greater in the cytoplasmic fraction (Figure 4C). 
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These bands were detected at 110 kDa and between 35 kDa and 45 kDa. Little tau expression 
was observed when the 4R tau antibody was used. Faint bands were detected at 20 kDa and 46 
kDa (Figure 4C).  
We then examined whether the 5FK fractionation protocol yielded the expected fractions, 
using GAPDH as a marker for the cytoplasmic fraction and histone H2A as a marker for the 
nuclear and chromatin-bound fraction. A strong positive band of 38 kDa is present in the 
cytoplasmic fraction for GAPDH, while less intense bands were found in the nuclear and 
chromatin fractions at approximately 17 kDa for H2A (Figure 5A).  
Figure 5. Antibody analyses of five subcellular fractions from SK-N-MC cells. 
Approximately 10 µg of DNA in each fraction was loaded onto a gel and then transferred onto a 
PVDF membrane. (A) Relative purity of the cytoplasmic (CY), nuclear (N), and chromatin-
bound (CH) fractions were confirmed using GAPDH and H2A antibodies. 
(B) Presence or absence of the tau isoforms located in the three fractions after exposure to the 
TAU-13 antibody. (C) Presence or absence of the 3R and 4R tau isoforms distributed in the three 
fractions. 
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Next, we investigated the distribution of the Total tau, the 3R tau, and the 4R tau 
isoforms in these fractions (Figure 5B, 5C). Analysis using an antibody against all tau isoforms 
(TAU-13) revealed that numerous tau isoforms were present in the cytoplasmic, chromatin, and 
nuclear fractions. The bands ranged in size between 35 kDa and 50 kDa (Figure 5B). Bands of 
similar sizes were found in all examined areas of the cell. The amount of tau was found to be 
greater in the cytoplasm, next greatest in the chromatin, and lowest in the nucleus (Figure 5B). A 
band indicating the Big Tau isoform was detected at approximately 110 kDa in all three 
fractions. When a 3R tau antibody was used for detection, similar detection patterns were 
observed in the cytoplasmic and chromatin fractions. Bands were detected between 35 kDa and 
45 kDa (Figure 5C). Very little tau expression was observed when the 4R tau antibody was used; 
however, faint bands may be detected at approximately 20 kDa and 46 kDa (Figure 5C).  
Relative Quantification of Tau Isoforms on Western Blot by Gel Densitometry  
Following antibody detection, a more quantified view of our results was seen as 
necessary to help understand the amount of each tau isoform in the cytoplasmic, nuclear, and 
chromatin fractions of the cell and to accurately compare these amounts to each other. Gel 
densitometry of membranes exposed to both a 3R tau antibody and a total tau antibody 
demonstrated low amounts of nuclear tau in SK-N-MC cells (Figure 6). Relative quantification 
of tau isoforms detected on a western blot exposed to a total tau antibody also demonstrated an 
increased amount of tau in the cytoplasm and chromatin fractions, adding up to be 83.34% of 
protein detected (Figure 6A). It was found that the tau isoform in “Band 1” predominates in the 
cytoplasmic fraction, measuring at 13.76% of total protein. It was also observed that the tau 
isoform detected in “Band 4” predominates in these fractions, measuring to be a total of 28.73% 
of protein on the membrane. 
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Figure 6. Relative quantification of tau isoforms by gel densitometry. Image Lab software 
(Bio-Rad) was used to quantify the amount of each tau isoform detected in the cytoplasm, 
nucleus, and chromatin of SK-N-MC cells. Percentages of protein in each fraction were 
calculated by comparing each band’s volume to the entire volume of bands in all three lanes. A) 
Relative quantification of proteins detected using a Total Tau antibody. B) Relative 
quantification of proteins detected using a 3R tau antibody. 
 
Relative quantification of proteins detected when a 3R tau antibody was used 
demonstrated an increased amount of 3R tau in the cytoplasm and chromatin of SK-N-MC cells, 
adding up to be 48.27% protein in the cytoplasm and 41.75% protein in the chromatin (Figure 
6B). Again, it was found that the tau isoform represented as “Band 1” predominates in the cell. 
Out of the remaining bands detected using a 3R antibody, it was observed that “Band 3” 
predominated in these fractions, adding up to be 20.06% of total protein. 
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Figure 7. Overlay of 3R tau antibody detection on total tau antibody detection. Imaging 
software was used to overlap the bands detected using both the 3R tau antibody and the Total tau 
antibody. The blue bands represent the 3R tau and the grey represents the Total tau. 
 
Patterns observed for Total Tau and 3R Tau in the cytoplasmic and chromatin fractions 
were very similar, but there were more bands detected when using a Total Tau antibody, 
suggesting that 4R isoforms are present (Figure 7). Using this overlay along with the relative 
quantifications of tau protein in each fraction, and the known molecular weights, we were able to 
identify which tau isoforms were detected in each fraction on the membranes (Table 2).  
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Figure 8. Visualizing the 
NOS1 probe. Lane 1 
contains the forward 
primer, lane 3 contains the 
reverse primer, and lane 2 
contains the two primers 
annealed together, forming 
the NOS1 probe. All lanes 
contain total 8.1 µg of 
DNA and are visualized on 
a 2% (w/v) agarose gel. 
1        2       3 
Table 2. Likely identifications of tau isoforms and detected bands on western blots.  
Total Tau Antibody 3R Tau Antibody 
Band 1 Big Tau Band 1 Big Tau 
Band 2 4R Tau Isoform   
Band 3 2N3R Band 2 2N3R 
Band 4 1N3R Band 3 1N3R 
Band 5 0N3R Band 4 0N3R 
Band 6 Small Isoform   
 
Electrophoretic Band Shift Assays: 
 Our lab has previously linked tau protein presence with changes in NOS1 
expression, though the mechanism by which this change in expression occurs is unknown. We 
designed EMSAs in order to determine if direct DNA binding by tau or another nuclear protein is 
the cause of this change in NOS1 
expression. The first step in creating an 
EMSA is to ensure an effective probe 
is utilized. This was investigated in 
Figure 8, visualizing the single the 
forward reverse strands for the NOS1 
probe on an agarose gel. Lanes 1 and 3 
contain the forward and reverse 
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A 1            2 B 1            2 
primers, respectively, and show far dimmer bands seen slightly above the band seen in lane 2. 
Lane 2 shows a very vivid band which contains both single strands after the annealing procedure, 
creating the NOS1 probe (Figure 8). 
Next, we began to visualize our probe when mixed with nuclear proteins. When highly 
degraded proteins are used in MSA samples, a complete lack of shifting is seen and can be 
utilized as a negative control (Figure 9A). An accompanying polyacrylamide gel run with the 
same protein samples showed no visible bands, indicating that all proteins had completely 
degraded (data not shown).  However, all EMSAs run with viable proteins (confirmed through 
visualization on a polyacrylamide gel, data not shown) showed MSA samples displaying a 
change in mobility. A representative figure is seen as Figure 9B. 
Figure 9. Non-denatured nuclear proteins slightly shift the NOS1 probe. For both (A) and (B), lane 1 
contains only the NOS1 probe. Lane A2 contains highly degraded nuclear proteins in Hepes buffer while 
lane B2 contains non-denatured nuclear proteins in Tris buffer. All samples were visualized on a 2% 
(w/v) agarose gel. 
 
Several EMSAs were conducted under varying conditions as described in the methods to 
create the most effective EMSA. In one EMSA comparing incubation time and buffer, all MSA 
samples showed a change in mobility with the exception of lane A2. Lane B3 also appeared 
 29 
dimmer than all other bands. No difference was seen between samples which had incubated for 
30 minutes (lane 2) and 90 minutes (lanes 3 and 4) (Figure 10).  
 
 
 
 
Figure 10. Investigating the effects of buffer type and incubation time on EMSAs. All samples were 
resolved on a 2% (w/v) agarose gel. Samples in lanes 1 and 5 are JDC and lanes 2-4 contain MSA 
samples using nuclear proteins (5FK, 21 µg). Lane 2 contains samples incubated for 30 minutes, while 
samples in lanes 3 and 4 were incubated for 90 minutes. A) Samples were run after incubation in PBS 
buffer. B) Samples were run after incubation in Tris buffer. 
  
 1       2      3       4        5 A   1       2       3       4       5 B 
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DISCUSSION 
Overall Discussion: 
The overall goal of this project was to further characterize tau’s presence and function in 
the nuclei of human cells. After fractionation of SK-N-MC cells, tau isoform presence was 
determined through western blotting and antibody analysis, and a potential DNA-binding role for 
tau was explored using EMSAs. 
Prior to exploring either aim, a reliable set of compartmentalized proteins was necessary. 
A major obstacle in obtaining these reliable proteins was sufficient compartmentalization. We 
found that in order to obtain well compartmentalized fractions, it was critical for the cell pellet to 
be left completely dry during each fractionation step before the addition of the following buffer 
solutions. This was accomplished through the second, short centrifugation after the removal of 
each fraction from the pellet as described in methods. This was done to ensure all liquid had been 
removed, and if it had not then we were able to remove it. Successful compartmentalization was 
achieved in Figure 4A and Figure 5A. In both analyses, the expected bands were detected when 
antibodies for GAPDH in the cytoplasm and H2A in the chromatin and nuclear fractions. This 
showed that acceptable fractionation occurred, with a large amount of GAPDH in the cytoplasm 
and very little in the nucleus and chromatin, and H2A only being present in the nucleus and 
chromatin. 
Throughout this project, protein degradation resulted in the largest reason for failure in 
obtaining results. The importance of maintaining viable proteins can be visualized in Figure 9, 
where a difference in mobility is seen when the sample contains known viable proteins and no 
difference in mobility is seen for a sample containing fully degraded proteins. The viable 
proteins were utilized in the pictured EMSA after roughly two weeks of storage, and the EMSA 
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containing degraded proteins was run after three weeks of storage (Figure 9). Another EMSA run 
with both Tris and Hepes incubation buffers after proteins had been stored for 7 weeks showed 
very slight changes in mobility with no difference between the incubation buffers, despite the 
samples in Tris buffer being treated exactly as they had been in Figure 10B (data not shown). 
Thus, a clear relationship between length of time stored and protein viability was not seen, but 
instead the treatment of the fractions prior to flash freezing was likely what led to degradation. 
Each fractionation sample was kept on ice until completion of the total protein assay, but if 
samples sat on ice for too long or extra care was not taken for the aliquot tubes to be made cold 
before the addition of each sample, degradation likely began prior to freezing. 
Aim 1: 
The goal of this aim was to determine the isoforms of tau normally found in the nucleus 
of human SK-N-MC cells. This was examined through the analysis of western blots using 
antibodies for total tau (TAU-13), 3R tau, and 4R tau. 
         Initial western blot analyses resulted in low intensity bands with a significant amount of 
background (data not shown). Switching secondary antibodies to one that contained horseradish 
peroxidase resulted in less background noise in comparison to using an alkaline phosphatase 
detection kit. In order to obtain stronger bands, varied antibody incubation times were used. We 
found that for the GAPDH, total tau (TAU-13), 3R tau, and 4R tau antibodies, one hour 
incubations at room temperature allowed for better detection. The best results with the H2A 
antibody were observed with overnight incubation at 4
0
C. 
  Although tau has primarily been described as a microtubule-associated protein with a 
preferential axonal localization, it has been observed in the nuclei and chromatin of human 
neuronal cells (Liu and Gotz, 2013). Antibody detection of the 2FK cytoplasmic and nuclear 
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fractions detected similar patterns of bands in these two fractions. When using the total tau 
(TAU-13) antibody, the same band pattern and intensity was observed in the cytoplasm and 
nuclear fractions. Detection with the 3R tau antibody resulted in similar bands in both fractions 
with an increased intensity in the cytoplasm, which, like in the 5FK proteins, suggests that while 
the same 3R isoforms are present, there is more 3R tau in the cytoplasm. We believe that this 
lesser prevalence of tau in the 2FK nuclear fraction is due to more of the nuclear tau being bound 
to DNA and thus not collected in this fraction. Comparison of the intensities of 2FK and 5FK 
cytoplasmic and nuclear fractions, respectively, appear almost identical, supporting this claim 
(Figures 4C, 5C). 
 Western blot analysis of the fractions obtained using the 5FK kit detected similar band 
distributions in the cytoplasm, nucleus, and chromatin of SK-N-MC cells when treated with 
Total Tau and 3R tau antibodies (Figure 5). The observed pattern in the nucleus was slightly less 
intense when compared with the cytoplasm and chromatin. These results suggest that the same 
tau isoforms are located in the cytoplasm, nucleus, and chromatin of neuronal cells, and also that 
the majority of nuclear tau binds to DNA instead of remaining free in the nucleus. This is in 
agreement with similar studies in mice (Liu and Gotz, 2013).  
Relative quantification of tau isoforms on western blots was measured using gel 
densitometry (Figure 6). Based on these results and the isoform identifications in Table 2, the 
Big Tau isoform had the greatest percentage of detected protein in the cytoplasmic fractions 
(Figure 6). This suggests that Big Tau does not have a high binding affinity for DNA or free-
floating nuclear tau. Higher percentages of tau protein in Band 4 of the membrane exposed to a 
total tau antibody and Band 3 of the membrane exposed to a 3R tau antibody suggest that the 
1N3R tau isoform is more predominate in the cell. This is interesting because the 1N4R isoform 
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was found to predominate in studies of mouse neurons (Liu, Gotz, 2013). The increased 
percentages of tau in the chromatin compared to the nucleus also suggests that a majority of 
nuclear tau is found to be bound to DNA, rather than remaining free in the nucleus. Most of the 
small tau isoforms also seemed to be present in the cytoplasmic, nuclear, and chromatin fractions 
(Figure 6). Further experimentation should be done to quantify the relative amounts of 4R tau 
isoforms in the nuclear and chromatin fractions to investigate the ratio of 3R tau to 4R tau in 
these cellular fractions. 
When exposure to both the total tau and the 3R tau antibody occurred, presence of the 
Big Tau isoform was detected. Research completed on the UCSC Genome Browser by Dr. 
Raymond Enke in the JMU Biology Department suggests that there is an increased amount of 
Big Tau in human SK-N-MC cells (Figure 11B). Increased big tau expression in SK-N-MC cells 
is thus noted at both the RNA and protein levels. 
Detection of 4R tau showed very little 4R tau was present in subcellular fractions from 
both fractionation kits (Figures 4C, 5C). Faint detection of 4R tau may be due in part to the 
quality of the 4R antibody as bands undetected by the 3R or 4R antibody were found in the total 
tau fractions (Figure 7). Moreover, UCSC Genome Browser RNA-sequencing by Dr. Raymond 
Enke illustrates a lower presence of 4R tau RNA in SK-N-MC cells in comparison to what is 
observed in the human brain (Figure 11C). While this would contribute to a higher difficulty of 
detection, we also believe our low detection was a result of the 4R tau antibody being of poor 
quality or the antibody degrading. Protein degradation may have occurred when separating the 
antibody into several aliquots. Similar studies have observed higher amounts of mature 4R tau in 
the SH-5Y-SY cell line (Smith et al). Further experimentation should be completed to investigate 
the amount of 4R tau in other neuronal-like mammalian tissue culture cells. 
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Figure 11. UCSC Genome Browser research from Dr. Raymond Enke showing RNA-
sequencing date comparing human brain RNA and SK-N-MC cells. In Fall 2017, Dr. 
Raymond Enke completed research on the UCSC Genome Browser. A) RNA-sequencing in 
human brain cells and SK-N-MC cells shows RNA transcripts as peaks, green and red 
respectively. The full transcript of the MAPT gene allows for comparison of exon expression in 
human brain RNA and SK-N-MC cells. Differing peak heights likely reflect differences in 
expression. B) It is of particular note that SK-N-MC cells appear to contain more exon 4A 
transcripts suggesting they have more Big Tau isoform.* C) It is of particular note that SK-N-
MC cells contain very little exon 10 transcripts suggesting they have little 4R tau isoform.* 
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The results of this aim suggest that there is similar distribution of tau isoforms in the 
cytoplasm, chromatin, and nucleus. It was found that both the 2FK and 5FK kits may be used to 
collect proteins, though in both cases the nuclear fraction contains a lesser amount of the same 
isoforms of tau. Gel densitometry of protein bands suggests that the Big Tau and 1N3R tau 
isoforms predominate in the cytoplasm of SK-N-MC cells. These findings suggests that a 
majority of nuclear tau may be bound to DNA, rather than free in the nucleus, further supporting 
tau’s potential role as a DNA binding factor.  
Aim 2: 
The goal of this aim was to learn how tau or another agent could regulate NOS1 gene 
expression through direct DNA binding. This was investigated through the development of 
effective EMSAs, with positive results obtained from creating the NOS1 probe and an EMSA 
varying incubation time and buffer type. 
         The formation of the NOS1 probe used in each EMSA was effective. Figure 8 shows the 
two single stranded pieces as far less intense bands appearing higher on the gel than the two 
strands annealed together. We expected to see the bands of both single strands lower on the gel 
as these are smaller molecules than double stranded molecules, however secondary structures 
may have formed from the single strands folding over on each other to cause a more irregular 
structure with lower mobility. To visualize the DNA, the gel was stained using ethidium 
bromide, a DNA intercalating agent, which fluoresces far brighter when inserted in between 
double stranded DNA than when associating with single stranded DNA (Fuller and Waring, 
1964). This property of ethidium bromide explains why the bands of single stranded pieces 
appeared far dimmer and what we believed to be a double stranded piece of DNA appear far 
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brighter. The band in lane 2 being so much brighter than either lane 1 or 3 determined that our 
annealing procedure was effective (Figure 9). 
         The EMSA which varied incubation time and buffer showed no difference in mobility for 
all MSA samples, with the exception of lane A2 (Figure 10). Lane B3 also showed a far dimmer 
band than all others, likely due simply to a mistake in pipetting into the gel. The absence of 
change in mobility for the sample in lane A2 can be explained by an insufficient amount of 
protein mixed with the sample. While mixing DNA and protein samples, this was the last sample 
mixed and received the last of the nuclear proteins we had collected and ended up being less than 
the total amount of proteins in other samples (Figure 10). This lack of a similar amount of total 
protein leading to a lack of shifting also gives support to our observations of degraded proteins 
leading to a lack of shifting. It is clear that at least 20 µg of total nuclear proteins is necessary to 
visualize an effective shift of the NOS1 probe. The requirement of a large amount of total protein 
may suggest that the protein causing the shift of the NOS1 probe is at a low concentration, or that 
multiple proteins are necessary to cause the shift of the NOS1 probe. Future experiments are 
necessary to further investigate the agent(s) causing the shift of the NOS1 probe. 
         In all EMSAs performed, a large amount of streaking was seen, both leading up to the 
band from the loading wells and a small amount following after the band, and the band was quite 
large and not very distinct. The presence of streaking in every lane, not just those with proteins 
mixed, leads us to believe that the streaking is from the NOS1 probe, not anything to do with the 
proteins that had been mixed with the NOS1 probe. We believe that streaking may be minimized 
through using less total DNA in our EMSAs. In one attempted EMSA which utilized Hepes 
buffer, a lesser amount of total DNA was used (5 µg, as opposed to 8.1 µg in previous EMSAs) 
and did not show any visible effect on mobility, streaking, or band size (data not shown). We 
 37 
believe in future studies, even less than 5 µg of DNA, potentially as low as 500 ng of DNA, 
should be attempted, as this may lead to a more distinct band with less streaking. 
Useful information for developing our EMSA technique was found each time an EMSA 
was attempted, even in those not presented as figures. In an EMSA previously mentioned, Hepes 
buffer appeared to be just as effective as the Tris buffer. In this same EMSA, both 5FK and 2FK 
fractions were used, and some lanes contained less of the nuclear fraction (some lanes contained 
15 µg and others contained the same as past EMSAs-- 20 µg). No difference was seen when 
proteins from either fractionation kit was used, however, when a lower amount of protein was 
used a smaller shift was observed. This EMSA was not presented as a figure due to the fact that 
shifts were barely seen, and thus the discussion of results from this EMSA are considered 
preliminary and require repetition for verification (data not shown). Using Hepes buffer also 
allowed for investigation in EMSA runtimes. Several different voltages and their resulting 
different runtimes were utilized with various EMSAs, and while distance traveled by the samples 
increased resolution and allowed mobility changes to be seen, no relationship was observed 
between runtime and magnitude of mobility change. Thus, any voltage can be used to visualize 
changes in mobility as long as the samples are run to the end of the gel. The greatest concern 
with higher voltages was that the running buffer and gel would warm and cause the DNA-protein 
interaction to break, or begin degrading the proteins entirely. Voltages even up to 120 V were 
seen to not warm the running buffer or gel as long as the apparatus was kept in the 4
0
 C cold 
room for the duration of the run (data not shown). Longer runtimes (>10 hours) were found to 
only be possible when our Hepes was used as the incubation buffer. All samples require a greater 
density than the running buffer in order to make sure that the sample remains in the gel and does 
not diffuse into the running buffer. All incubation buffers besides Hepes required mixing with 
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loading dye to give the sample its required density, but Hepes contained a much higher 
concentration of glycerol, giving it a far greater density and allowing it to remain in the gel for 
longer. Samples mixed with loading dye were observed to diffuse out after 10 hours, but samples 
mixed with the Hepes buffer were able to remain in the agarose gel for at least 4 days without 
losing any sample (data not shown). 
Other variables attempted to observe changes in mobility included varying protein 
amount from 5-25 µg, varying MgCl2 concentration from 1-20 mM in the incubation buffer, 
using cytoplasmic proteins as opposed to nuclear proteins, and attempting a supershift with our 
total tau antibody (TAU-13). The EMSA varying protein amount was intended to confirm our 
observation that protein amount seems to be the largest factor in the amount of mobility change 
seen. Varying the concentration of MgCl2 was to be the first of several EMSAs investigating the 
ideal incubation buffer for observing a change in the NOS1 probe’s mobility. MgCl2 is an 
important buffer ingredient for our investigations as the concentration of MgCl2 can change the 
structure of R/Y repeat sequences of DNA from B-DNA to Z-DNA. Lower salt concentrations 
can create an environment in which the B-DNA predominates, and higher salt concentrations can 
form an environment in which the Z-DNA form predominates (Bothe et al., 2011). Tau is known 
to have an affinity towards both forms, however if tau is shown to bind this sequence in the Z-
DNA form that could more strongly connect it into the narrative of tau causing the excess of Z-
DNA seen in AD brains by stabilizing many of the genes related to AD with R/Y repeats into Z-
DNA. The use of cytoplasmic proteins in an EMSA could have provided some indirect evidence 
that tau is binding to the NOS1 probe as it is found in roughly equal amounts in the cytoplasm 
and nucleus (Figure 5). Finally, a supershift could have confirmed or denied tau’s involvement in 
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the shifting of the NOS1 probe. Unfortunately, no results were found in all of these attempts due 
to protein degradation (data not shown). 
Future EMSAs should explore the aforementioned parameters for which results were not 
obtained due to protein degradation, as well as repeat the EMSA involving the Hepes buffer to 
verify the conclusions drawn from that data, continue varying other incubation buffer pH and 
ingredients (DNA amount, protein amount, concentration of KCl, addition of a non-competitive 
DNA binder), an attempt at a crude purification of tau should be made to see if mobility shifts 
improve with a fewer number of total proteins, and finally a fully purified sample of tau or use of 
the total tau antibody must be completed in order to determine if this is the agent binding the 
NOS1 probe. 
It is very possible that future EMSAs may show tau is not directly binding to the NOS1 
probe, or that multiple molecules, including tau or not including tau, are binding to the NOS1 
probe. Any result, whether it is tau or not binding the NOS1 probe, would still be very important 
in understanding why the R/Y repeat of NOS1 is required for a change in expression to occur due 
to tau’s presence. If a molecule besides tau was found to be binding the NOS1 probe, this may 
determine a completely new role for tau in the nucleus as regulating some unknown nuclear 
protein, furthering our knowledge of tau in the nuclei of neurons. The identity of that protein 
could also be determined through EMSAs using various purified nuclear samples. There is still 
far more room for discovery in this area. 
From our successful EMSAs, we have learned that something in the nuclear fraction of 
SK-N-MC cells is capable of causing a slight shift in the NOS1 probe, suggesting direct DNA 
binding, though we have not identified this protein (Figure 8). We have also learned that there is 
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not a great difference seen between the Tris and PBS buffers, and sample incubation can occur 
for only 30 minutes and effective shifts are still seen (Figure 9). 
Final Conclusions: 
         The goal of this project, to further investigate tau’s presence and function in the nucleus 
of human neuronal cells, was successfully accomplished. We determined that the same 3R 
isoforms are present in the cytoplasm, nucleus, and chromatin of SK-N-MC cells. It was also 
found in Aim 1 that a large majority of nuclear tau is found to be bound to DNA, as especially 
the 1N3R isoform, rather than remaining free in the nucleus, providing new evidence to support 
tau’s role as a DNA binding factor. And, in Aim 2, advances were made in the development of 
methods to investigate tau’s direct binding ability to a common repeat found in the promoters of 
many genes involved in Alzheimer’s. 
 While future studies directly related to each specific aim have already been stated, there 
are many other studies to further our knowledge of tau in the nucleus that do not pertain 
specifically to either aim. As demonstrated in our results, the Big Tau isoform predominates in 
the cytoplasm of non-neuronal cells. Although many studies have not been done on the role of 
this isoform, further experimentation should be done to identify the role of the extra exons 
present in Big Tau and understand how they may keep this form of tau out of the nucleus. A 
common practice in order to determine the function of a protein is to create a knockout cell line 
missing the gene for the desired protein. Experiments have already begun in our lab utilizing the 
CRIPSR-Cas9 system in order to obtain SK-N-MC knockouts for various isoforms of tau. These 
cells would allow for a large variety of experiments to determine what tau could normally be 
doing, such as analyzing differences in expression of several genes involved in Alzheimer’s 
between tau knockout cells and wild-type cells. 
 41 
APPENDIX I. Gel densitometry protocol adapted from the Bio-Rad Image Lab software 
user guide.  
 First, open the image of the exposed membrane in the Image Lab software. With your 
image open in the workspace, click Lane and Bands in the Analysis Toolbox located on the left 
panel. 
To detect lanes… 
1. To detect a specific number of lanes, click Manual and enter the number of lanes you 
want to find.  
2. Lanes may be moved around to better fit what is detected on your membrane. To move 
one or more selected lanes, place the pointer on a selected lane and drag it to a new 
position. If you select multiple lanes at once, they will all move together.  
3. To resize a lane, first select the lane you want to edit and white anchor points will 
become visible. Point to an anchor on the side of the lane and drag the anchor to change 
the lane width to your liking. To resize lanes to a width you specify, in the lanes tab enter 
a width in millimeters and click Set Width.  
To detect bands… 
1. First, click “Detect Bands” in the Lane and Bands setting in the Analysis Toolbox. 
2. To manually add a band to a lane, use the “Add” feature in the Bands tab. First, click add 
and then click inside the lane where you would like to define a band.  
3. To delete a band, click delete on the Bands tab and then click the band you want to 
remove.  
4. You may use the adjust feature to display boundary lines above and below each band. 
Move the pointer over a boundary line until the cursor changes to a double-pointed 
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arrow. Move the boundary line to adjust the band height. Image Lab will reposition the 
band and recalculate its center.  
 
Once your desired number of lanes and bands have been defined, click the “Report” on the 
toolbar. This will create a file including your membrane image with the defined lanes and bands 
along with a series of tables containing the volume measurements of each band.  
To calculate relative percentage of protein detected in each band… 
1. First make sure to record each volume measurement calculated in the Report from Image 
Lab. 
2. Add together the volume measurements of all bands detected on your membrane. 
Divide each individual band volume by the total volume of protein detected on the 
membrane and multiply this by 100 to make it a percentage. 
  
 43 
LITERATURE CITED 
 
Alzheimer’s Association (2018). Latest Facts & Figures Report. 
 
Barghorn, S., Biernat, J., and Mandelkow, E. (2005). Purification of Recombinant Tau Protein and 
Preparation of Alzheimer-Paired Helical Filaments In Vitro. In Methods in Molecular Biology, 
E. Slgurdrron, ed. (Totowa, NJ: Humana Press, Inc.), pp. 35–51. 
 
Berman, J., Eisenberg, S., and Tye, B. (1987). An agarose gel electrophoresis assay for the detection 
of DNA-binding activities in yeast cell extracts. Methods Enzymol. 155, 528–537. 
 
Bothe, J.R., Lowenhaupt, K., and Al-Hashimi, H.M. (2011). Sequence-specific B-DNA flexibility 
modulates Z-DNA formation. J. Am. Chem. Soc. 133, 2016–2018. 
 
Bukar Maina, M., Al-Hilaly, Y., and Serpell, L. (2016). Nuclear Tau and Its Potential Role in 
Alzheimer’s Disease. Biomolecules 6, 9. 
 
Corces, V., Manso, R., De, J., Torre, L., Avila, J., Nasr, A., and Wiche, G. (1980). Effects of DNA 
on Microtubule Assembly. Eur. J. Biochem. 105, 7–16. 
 
Dent, C.L., and Latchman, D.S. (1993). No Title. In Transcription Factors: A Practical Approach, 
D.S. Latchman, D. Rickwood, and B. Hames, eds. (Oxford, NY: Oxford University Press), pp. 
1–26. 
 
Duan, Y., Dong, S., Gu, F., Hu, Y., and Zhao, Z. (2012). Advances in the Pathogenesis of 
Alzheimer’s Disease: Focusing on Tau-Mediated Neurodegeneration. Transl. Neurodegener. 1, 
24. 
 
Fuller, W., and Waring, M. (1964). A Molecular Model for the Interaction of Ethidium Bromide 
with Deoxyribonucleic Acid. Berichte Der Bunsengesellschaft Für Phys. Chemie 68, 805–808. 
 
Galimberti, D., Scarpini, E., Venturelli, E., Strobel, A., Herterich, S., Fenoglio, C., Guidi, I., 
Scalabrini, D., Cortini, F., Bresolin, N., et al. (2008). Association of a NOS1 promoter repeat 
with Alzheimer’s disease. Neurobiol. Aging 29, 1359–1365. 
 
Goedert, M., Spillantini, M., Jakes, R., Rutherford, D., and Crowther, R. (1989). Multiple isoforms 
of human microtubule-associated protein tau: sequences and localization in neurofibrillary 
tangles of Alzheimer’s disease. Neuron 3, 519–526. 
 
Goedert, M., Spillantini, M., and Crowther, R. (1992). Cloning of a big tau microtubule-associated 
protein characteristic of the peripheral nervous system. Proc. Natl. Acad. Sci. U. S. A. 89, 1983–
1987. 
 
Guillozet, A., Weintraub, S., Mash, D., and Mesulam, M. (2003). Neurofibrillary tangles, amyloid, 
and memory in aging and mild cognitive impairment. Arch. Neurol. 60, 729. 
 44 
 
Guo, T., Noble, W., and Hanger, D. (2017). Roles of tau protein in health and disease. Acta 
Neuropathol. 133, 665–704. 
 
Hall, A., Antoniou, H., Wang, Y., Cheung, A., Arbus, A., Olson, S., Lu, W., Kau, C., and Marsden, 
P. (1994). Structural organization of the human neuronal nitric oxide synthase gene (NOS1). J. 
Biol. Chem. 269, 33082–33090. 
 
Hanger, D., Lau, D., Phillips, E., Bondulich, M., Guo, T., Woodward, B., Pooler, A., and Noble, W. 
(2014). Intracellular and extracellular roles for tau in neurodegenerative disease. J. Alzheimers. 
Dis. 40, S37-45. 
 
Hardy, J., and Selkoe, D. (2002). The Amyloid Hypothesis of Alzheimer’s Disease: Progress and 
Problems on the Road to Therapeutics. Science. 297, 353–356. 
 
Iqbal, K., Liu, F., Gong, C., and Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related 
tauopathies. Curr. Alzheimer Res. 7, 656–664. 
 
Janke, C., Holzer, M., Klose, J., and Arendt, T. (1996). Distribution of isoforms of the microtubule-
associated protein tau in grey and white matter areas of human brain: A two-dimensional 
gelelectrophoretic analysis. FEBS Lett. 379, 222–226. 
 
Kimpara, T., Takeda, A., Watanabe, K., Itoyama, Y., Ikawa, S., Watanabe, M., Arai, H., Sasaki, H., 
Higuchi, S., Okita, N., et al. (1997). Microsatellite polymorphism in the human heme oxygenase-
1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. 
Hum. Genet. 100, 145–147. 
 
Lambert, J., Pasquier, F., Cottel, D., Frigard, B., Amouyel, P., and Chartier-Harlin, M.-C. (1998). A 
new polymorphism in the Apoe promoter associated with risk of developing Alzheimer’s 
disease. Hum. Mol. Genet. 7, 533–540. 
 
Lee, V., Goedert, M., and Trojanowski, J. (2001). Neurodegenerative tauopathies. Annu. Rev. 
Neurosci. 24, 1121–1159. 
 
Lippens, G., Landrieu, I., Smet, C., Huvent, I., Gandhi, N., Gigant, B., Despres, C., Qi, H., and 
Lopez, J. (2016). NMR Meets Tau: Insights into Its Function and Pathology. Biomolecules 6, 28. 
 
Liu, C., and Götz, J. (2013). Profiling Murine Tau with 0N, 1N and 2N Isoform-Specific Antibodies 
in Brain and Peripheral Organs Reveals Distinct Subcellular Localization, with the 1N Isoform 
Being Enriched in the Nucleus. PLoS One 8, e84849. 
 
Prast, H., and Philippu, A. (2001). Nitric oxide as modulator of neuronal function. Prog. Neurobiol. 
64, 51–68. 
 
  
 45 
Qi, H., Cantrelle, F.-X., Benhelli-Mokrani, H., Smet-Nocca, C., Buée, L., Lippens, G., Bonnefoy, E., 
Galas, M.-C., and Landrieu, I. (2015). Nuclear Magnetic Resonance Spectroscopy 
Characterization of Interaction of Tau with DNA and Its Regulation by Phosphorylation. 
Biochemistry 54, 1525–1533. 
 
Rife, T., Rasoul, B., Pullen, N., Mitchell, D., Grathwol, K., and Kurth, J. (2009). The effect of a 
promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to 
Parkinson’s disease. J. Neurosci. Res. 87, 2319–2325. 
 
Sotiropoulos, I., Galas, M., Silva, J., Skoulakis, E., Wegmann, S., Maina, M., Blum, D., Sayas, C., 
Mandelkow, E., Mandelkow, E., et al. (2017). Atypical, non-standard functions of the 
microtubule associated tau protein. Acta Neuropathol. Commun. 5, 91. 
 
Sultan, A., Nesslany, F., Violet, M., Bégard, S., Loyens, A., Talahari, S., Mansuroglu, Z., Marzin, 
D., Sergeant, N., Humez, S., et al. (2011). Nuclear Tau, a Key Player in Neuronal DNA 
Protection. J. Biol. Chem. 286, 4566–4575. 
 
Toda, N., and Okamura, T. (2003). The Pharmacology of Nitric Oxide in the Peripheral Nervous 
System of Blood Vessels. Pharmacol. Rev. 55, 271–324. 
 
Ueki, A., Ueno, H., Sato, N., Shinjo, H., and Morita, Y. (2007). Serotonin transporter gene 
polymorphism and BPSD in mild Alzheimer’s disease. J. Alzheimer’s Dis. 12, 245–253. 
 
Vasudevaraju, P., Guerrero, E., Hedge, M., Collen, T., Bitton, G., and Rao, K. (2012). New evidence 
on α-synuclein and Tau binding to conformation and sequence specific GC* rich DNA: 
Relevance to neurological disorders. J. Pharm. BioAllied Sci. 4, 112. 
 
Weaver, T., and Deal, A. (2016). Modulation of Nitric Oxide Synthase I Transcription by Tau and 
Alpha-Synuclein and its Relevance to Alzheimer’s and Parkinson’s Diseases. James Madison 
University. 
 
Zahler, A., Neugebauer, K., Lane, W., Roth, M., Reed, L., Miller, B.I., Geschwind, D.H., Bird, T.D., 
McKeel, D., Goate, A., et al. (1993). Distinct functions of SR proteins in alternative pre-mRNA 
splicing. Science. 260, 219–222. 
 
